Navigation Links
Adamas Pharmaceuticals To Report Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia In Parkinson's Disease
Date:6/10/2013

EMERYVILLE, Calif., June 10, 2013 /PRNewswire/ -- Adamas Pharmaceuticals, Inc. announced today that the Company's Phase 2/3 EASED (Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia) clinical trial of ADS-5102 (Nurelin; amantadine HCl extended release) met the study's primary endpoint.  ADS-5102 is an investigational extended-release formulation of amantadine intended for once-nightly administration that is being evaluated for the treatment of levodopa-induced dyskinesia (LID) in Parkinson's disease (PD) patients. 

"I am pleased to report our Phase 2/3 EASED study of ADS-5102 for the treatment of LID in Parkinson's disease met the study's primary endpoint with statistical significance," said Gregory T. Went, Ph.D., Chief Executive Officer of Adamas.  "We look forward to sharing the clinical results from the EASED trial of ADS-5102 at the upcoming International Congress of Parkinson's Disease and Movement Disorders."  

Data from the Phase 2/3 EASED clinical study of ADS-5102 have been accepted for presentation at the 17th International Congress of Parkinson's Disease and Movement Disorders taking place on June 16-20, 2013 in Sydney, Australia.  Rajesh Pahwa, M.D., Professor of Neurology, University of Kansas Medical Center and an investigator for the EASED study will present the final results during the "Parkinson's Disease: Clinical Trials" session in a poster entitled Randomized Trial of Extended Release Amantadine in Parkinson's Disease Patients with Levodopa-induced Dyskinesia (EASED Study) (abstract #443) on June 18, 2013 at 12:30 pm AEST.

About the EASED Study
The EASED study was a randomized, double-blind, placebo-controlled clinical trial that enrolled 83 Parkinson
'/>"/>

SOURCE Adamas Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda™
2. Access Pharmaceuticals Signs US License Agreement With AMAG Pharmaceuticals For MuGard
3. HemaQuest Pharmaceuticals Completes Patient Enrollment in Phase 2b Clinical Study of HQK-1001 in Patients with Sickle Cell Disease
4. Oramed Pharmaceuticals to Present at IATI-BioMed Conference in Israel
5. DelMar Pharmaceuticals, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
6. Valeant Pharmaceuticals Announces Filing Of Preliminary Base Shelf Prospectus
7. Ampio Pharmaceuticals Issues Statement Regarding Misleading Blog
8. Actinium Pharmaceuticals, Inc. Receives $3.5m from Exercise of Warrants
9. Piramal Imaging Highlights New Data for Florbetaben and Other Investigational Radiopharmaceuticals at SNMMI 2013
10. Ampio Pharmaceuticals to List on the NYSE MKT
11. Isis Pharmaceuticals Earns $6 Million Payment from AstraZeneca
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... EASTON, Mass. , Sept. 19, 2014 /PRNewswire/ ... "Company") today announced it has received and approved ... Barozyme HT48 instruments and has begun to manufacture ... the first instrument will be ready for shipment ... be built and released at a rate of ...
(Date:9/19/2014)... 19, 2014 Aufgrund der ... äußerst erfolgreichen Serialisierungs-Countdown-Kalender aktualisiert, der jetzt auch die ... verfügbar unter pharmaserialisation.com , zeigt die Serialisierungsanforderungen ... in Kraft treten. Für international tätige ... um das "ob", sondern darum, "wann" sie die ...
(Date:9/19/2014)... and CAMBRIDGE, Mass. ... Inc. (PGDx), a provider of advanced cancer ... Medicines , a leader in discovering and developing ... today disclosed the first-ever comprehensive genomic study of ... deadly cancer of the female reproductive system, also ...
Breaking Medicine Technology:Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 2Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 3Pharma IQ stellt weltweite Serialisierungsfristen in seinen Countdown-Kalender 2014 - 2018 2First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 2First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 3First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 4
(Date:9/19/2014)... 2014 BCC Research reveals in its ... MARKETS , the global market for human antifungal therapeutics ... 2018, with a five-year compound annual growth rate (CAGR) ... at a steady 3.8% CAGR. , Given the current ... coupled with the incidence of increasing mortality and the ...
(Date:9/19/2014)... (PRWEB) September 19, 2014 Ticket Down ... tickets for her 2015 “Honeymoon” Tour. This popular ... for additional savings at the checkout. , Ariana Grande 2015 ... (Independence Event Center) , Feb. 28, 2015: Milwaukee, WI (BMO ... (Xcel Energy Center) , March 03, 2015: Chicago, IL (Allstate ...
(Date:9/19/2014)... An ultrasensitive biosensor made from the wonder material graphene ... increased risk of developing cancer. , The biosensor ... more sensitive than bioassay tests currently in use, and ... minutes, opening up the possibility of a rapid, point-of-care ... presented today, 19 September, in IOP Publishing,s journal ...
(Date:9/19/2014)... Follow us on LinkedIn ... detection and quantification of the presence of antigens ... steady expansion in immunodiagnostics and technological advancements in ... market has evolved remarkably well over the years. ... cardio-vascular ailments, infectious diseases, allergy and cancer, continue ...
(Date:9/19/2014)... 19, 2014 Recent financial data ... industry increased their sales by 7% in the last ... trucking industry can be used as a bellwether to ... whole. This data has been proven to show trends ... freight transportation. Other non-trucking data is largely influenced by ...
Breaking Medicine News(10 mins):Health News:Global Market for Human Antifungal Therapeutics to Reach Nearly $13.9 Billion in 2018; Over-The-Counter (OTC) Segment Growing At 3.8% CAGR 2Health News:Global Market for Human Antifungal Therapeutics to Reach Nearly $13.9 Billion in 2018; Over-The-Counter (OTC) Segment Growing At 3.8% CAGR 3Health News:Ariana Grande Tickets in Miami, Philadelphia, Chicago, Saint Paul, Fairfax, Uncasville, Orlando, San Jose, New York, Detroit, San Antonio, Pittsburgh, Atlanta & Dallas 2Health News:Ariana Grande Tickets in Miami, Philadelphia, Chicago, Saint Paul, Fairfax, Uncasville, Orlando, San Jose, New York, Detroit, San Antonio, Pittsburgh, Atlanta & Dallas 3Health News:Ariana Grande Tickets in Miami, Philadelphia, Chicago, Saint Paul, Fairfax, Uncasville, Orlando, San Jose, New York, Detroit, San Antonio, Pittsburgh, Atlanta & Dallas 4Health News:Graphene sensor tracks down cancer biomarkers 2Health News:Growing Preference for Non-Invasive Diagnostics Spurs Growth in the Global Immunoassay Systems Market, According to New Report by Global Industry Analysts, Inc. 2Health News:Growing Preference for Non-Invasive Diagnostics Spurs Growth in the Global Immunoassay Systems Market, According to New Report by Global Industry Analysts, Inc. 3Health News:Growing Preference for Non-Invasive Diagnostics Spurs Growth in the Global Immunoassay Systems Market, According to New Report by Global Industry Analysts, Inc. 4Health News:LeaseQ Announces Good News For The Truck Leasing Industry As Truck Rentals In The U.S Continues to Gain Traction 2Health News:LeaseQ Announces Good News For The Truck Leasing Industry As Truck Rentals In The U.S Continues to Gain Traction 3
... Institute along with the Hong Kong Cleft Lip and Palate ... for congenital facial deformities in the city of Chennai//. The ... Samman, Director of the Hong Kong Cleft Lip & Palate ... Surgeons. , ,The center has tied up with Hong ...
... the 'Bambach Saddle Seat' invented by Australian therapist Mary Gale, ... ,The chair, which is priced at 399 pounds, was found ... positions the pelvis correctly. ,Each person tested was ... backwards slightly and given a task to perform. This was ...
... blamed for obesity by a study in Florida. The study was ... fructose present in fruits//, honey and other natural sources might be ... that Fructose makes beleive that the subject is hungrier than actually ... ,The study in animals have revealed that fructose has a ...
... persistent pain may be increased by an inflamed injury, according ... even after it has disappeared//. Several million Canadians are reported ... has published the study. The NR2B proteins in mice are ... to imprint upon the brain a painful response even when ...
... 2025, the number of people in Britain over the age ... pensions and pensioner spending power will increase. Answers to problems//, ... ,In a move to address the issues of ageing ... our lives, the Economic and Social Research Council (ESRC) is ...
... ,The disabled, homeless man who died on ... sub-zero temperatures had refused the help of paramedics, say ... the paramedics on Saturday night did actually respond to ... and the patient clearly refused any assistance from the ...
Cached Medicine News:Health News:New Chair Invented To Relieve Backache 2Health News:Fructose is a tricker and not all that sweet! 2Health News:ESRC offers new dynamics for old in UK 2Health News:ESRC offers new dynamics for old in UK 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: